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The pathogenesis of human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) is mediated
mainly by mononuclear phagocyte (MP) secretory products and their interactions with neural cells. Viral
infection and MP immune activation may affect leukocyte entry into the brain. One factor that influences
central nervous system (CNS) monocyte migration is matrix metalloproteinases (MMPs). In the CNS, MMPs
are synthesized by resident glial cells and affect the integrity of the neuropil extracellular matrix (ECM). To
ascertain how MMPs influence HAD pathogenesis, we studied their secretion following MP differentiation,
viral infection, and cellular activation. HIV-1-infected and/or immune-activated monocyte-derived macro-
phages (MDM) and human fetal microglia were examined for production of MMP-1, -2, -3, and -9. MMP
expression increased significantly with MP differentiation. Microglia secreted high levels of MMPs de novo
that were further elevated following CD40 ligand-mediated cell activation. Surprisingly, HIV-1 infection of
MDM led to the down-regulation of MMP-9. In encephalitic brain tissue, MMPs were expressed within
perivascular and parenchymal MP, multinucleated giant cells, and microglial nodules. These data suggest that
MMP production in MP is dependent on cell type, differentiation, activation, and/or viral infection. Regulation
of MMP expression by these factors may contribute to neuropil ECM degradation and leukocyte migration
during HAD.
Pathogenic mechanisms for human immunodeficiency virus
type 1 (HIV-1)-associated dementia (HAD) revolve around
the secretion of neurotoxic products by immune-activated
mononuclear phagocytes (MPs), which include microglia and
perivascular and parenchymal brain macrophages (17, 24). Im-
mune-activated MPs, a critical pathological correlate of HAD
(25), secrete a number of neurotoxins including eicosanoids
(arachidonic acid and its metabolites), quinolinic acid, platelet
activating factor, tumor necrosis factor alpha (TNF-a), nitric
oxide, and matrix metalloproteinases (MMPs) (5, 15, 19, 41,
42). All can affect HAD pathogenesis (5, 15, 26, 28, 58, 61).
Indeed, MP products often lead to alterations in adhesion
molecules, cytokines, and chemokines in endothelial cells,
MPs, and astrocytes.
MMPs produced as a consequence of MP activation can
compromise blood-brain barrier (BBB) integrity and influence
monocyte transmigration into the brain. MMPs are proteolytic
enzymes responsible for the maintenance, turnover, and integ-
rity of the extracellular matrix (ECM) (30). MMP dysregula-
tion can affect tissue remodeling and organ homeostasis (38,
65). In response to inflammation and cellular activation,
MMPs are synthesized by a variety of cell types (4, 49) includ-
ing endothelial and epithelial cells (13, 64), leukocytes (14, 23,
34, 46), neural cells (38), and hepatocytes (47). Cytokines (11),
cell differentiation (6, 48, 60), and viral infection (11, 55) affect
the regulation of MMPs. When produced in abundance,
MMPs affect cell signaling triggered by integrins (53). Methods
for detection of MMP enzymatic activities are highly divergent,
and each assay system (molecular, enzyme-linked immunosor-
bent assay [ELISA], and zymography) measures distinct as-
pects of their function (43).
To explore how MMPs are regulated during HAD, we stud-
ied their biological activities in the natural target cells of
HIV-1 in brain, the MPs. Pure populations of primary human
monocyte-derived macrophages (MDMs) and microglia were
used to study the effects of cellular differentiation and immune
activation on MMP production. CD40 ligand (CD40L) was
utilized to induce MP activation, because it has been shown to
be upregulated in plasma and on CD41 T lymphocytes during
HAD. Importantly, ligation of the CD40 receptor on human
endothelial cells upregulates the expression of leukocyte ad-
hesion molecules (37). In addition, CD40L can effect micro-
glial activation in Alzheimer’s disease (57). MMPs were de-
tected by reverse transcriptase PCR (RT-PCR), ELISA, and
gelatin zymography tests. Differentiating monocytes and cul-
tured microglia produced high levels of MMP-9. Microglial
cells generated higher levels of MMPs de novo. CD40L-in-
duced immune activation potentiated MMP production early
after MP differentiation and/or cell cultivation. HIV-1 infec-
tion of MPs reduced MMP production, while CD40L activa-
tion increased it. Analysis of human autopsy tissue by RT-PCR
* The Center for Neurovirology and Neurodegenerative Disorders,
Departments of Pathology and Microbiology, 985215 Nebraska Med-
ical Center, Omaha, NE 68198-5215. Phone: (402) 559-5275. Fax:




analysis showed that the levels of both MMP-9 and MMP-2
transcripts were increased during HIV-1 encephalitis (HIVE)
and that these increases correlated with the CD14 mRNA
levels, indicating that the upregulation observed in HIVE brain
tissue is mainly due to the infiltrating MPs. Immunohistochem-
ical analysis performed on brain tissue from patients who died
of HIVE demonstrated MMP antigen expression in infected
brain tissue. Both MMP-9 and MMP-2 were found in multinu-
cleated giant cells, microglial nodules, and in close proximity to
brain microvessels. An understanding of the processes involved
in MMP production should provide unique insights into what
controls monocyte infiltration across the BBB and the degra-
dation of neuropil ECM during HAD.
MATERIALS AND METHODS
Isolation and propagation of monocytes. Peripheral blood mononuclear cells
were obtained from HIV-1, HIV-2, and hepatitis B-seronegative donors by
leukopheresis, and then monocytes were purified by countercurrent centrifuga-
tion (16). Cell suspensions were .98% pure monocytes by Wright staining,
nonspecific esterase, granular peroxidase, and CD68 immunostaining. Cells were
cultured in Dulbecco’s modified Eagle’s medium (Sigma) supplemented with
10% heat-inactivated pooled human serum, 10 mg of ciprofloxacin per ml (Sig-
ma), 50 mg of gentamicin per ml (Sigma), and 1,000 U of macrophage colony-
stimulating factor (MCSF) per ml (a generous gift from Genetics Institute,
Cambridge, Mass.) for 7 days and thereafter maintained in MCSF-free medium.
All reagents were prescreened and found negative for endotoxin (,10 pg/ml;
Associates of Cape Cod, Woods Hole, Mass.) and mycoplasma contamination
(Gen-probe II, Gen-probe, San Diego, Calif.).
Isolation and propagation of microglia. Human fetal microglial cells were
prepared as described previously with some modifications (21, 22). Briefly, fetal
brain tissue (gestational age, 14 to 19 weeks) was obtained after elective abortion
procedures performed in full compliance with National Institutes of Health and
University of Nebraska Medical Center ethical guidelines. The tissue was di-
gested with 0.25% trypsin (Sigma) for 30 min at 37°C. The resultant single-cell
suspension was cultured in Dulbecco’s modified Eagle’s medium (Sigma) sup-
plemented with 10% heat-inactivated fetal bovine serum, penicillin-streptomycin
(50 mg/ml), and 100 mg of neomycin per ml for 7 days. Released microglia were
collected and purified by preferential adhesion and identified as .98% pure by
CD68 immunostaining. Purified microglial cells were cultured in the presence of
MCSF (1,000 U/ml) for 7 days in parallel with monocytes derived from elutria-
tion.
Viral strains and MP activators. The viral strains HIV-1ADA (16) and HIV-
1DJV (27) have been described previously. HIV-1YU-2 (33), HIV-1JR-FL (31), and
HIV-1SF162 (7) were obtained from the AIDS Research and Reference Program,
National Institute of Allergy and Infectious Diseases. HIV-1MSCSF was recently
isolated at the Center for Neurovirology and Neurodegenerative Disorders from
cerebrospinal fluid of an HAD patient (18).
All HIV-1 isolates were propagated on MDMs. Soluble trimeric CD40L was a
generous gift from Immunex Corp., Seattle, Wash.
HIV-1 infection of MDMs and microglia. Monocytes and microglia were
cultured on 96-well plates (Costar Corp., Cambridge, Mass.) at a density of 105
cells/well for 7 days prior to viral infection. The cell-free viral inoculum was
standardized for all experiments by RT activity (2 3 105 cpm/106 cells). Adherent
monolayers of monocytes and microglia were incubated with virus for 4 h at
37°C. Culture medium was exchanged twice weekly. RT was determined every 2
to 3 days with 10 ml of culture supernatant (21).
Immune stimulation of MDMs and microglia. Adherent monolayers of mono-
cytes and microglia were stimulated on specific days following cell culture. For all
experiments, cells were maintained in MCSF-free medium after 7 days. Serum-
free medium was placed into the MP cultures prior to zymography for collection
of supernatant samples. Select cells were treated with 2 mg of CD40L per ml for
the entire experiment. Untreated cells were used as controls.
RT-PCR tests. Levels of MMP RNA in uninfected and infected CD40L-
treated MDM, untreated controls, and human brain autopsy tissue were deter-
mined after reverse transcription with antisense primers and PCR amplification
of the cDNA. RNA for the cellular gene actin served as an internal standard.
Data were quantitated by the Molecular Dynamics PhosphorImager Storm sys-
tem, with results normalized to actin products. Amplified DNAs were identified
by Southern blotting (10). Briefly, total cellular RNA (0.7 mg) in 2.5 ml was mixed
with 0.5 mg of antisense primers. The mixture was heated at 70°C for 10 min and
then cooled to 4°C. RT (200 U/ml; Life Technologies) and 1.5 ml (each) of the
four deoxynucleotide triphosphates (10 mM; Perkin-Elmer) were added. RT
reactions were performed at 37°C for 15 min and were terminated by heating the
sample to 95°C. For PCR amplification of the cDNAs, 0.5 mg of sense primers
and 0.25 mg of antisense primers were added, with 1 ml each of the four de-
oxynucleotide triphosphates and 0.5 ml of Amplitaq DNA polymerase (5 U/ml;
Perkin-Elmer). Denaturation was performed at 95°C for 2 min followed by 28
amplification cycles (94°C for 30 s, 50°C for 30 s, 72°C for 1 min each). Products
were reannealed at 72°C for 5 min. The final reaction mix was held at 4°C.
ELISA determinations of MMPs. MMP-1, -2, -3, and -9 were assayed with
ELISA kits (Amersham, Arlington Heights, Ill., and Oncogene Research Labo-
ratories, Cambridge, Mass.) following the manufacturer’s instructions. For ex-
periments involving HIV-1 infection, the values obtained were normalized to the
cell number on the basis of MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltet-
razolium bromide) activity. Statistical analyses were performed with GraphPad
Prism 2.0, with one-way analysis of variance (ANOVA), and Newman-Keuls
posttest.
Gelatin zymography. Zymography was performed as described previously (10).
Samples were analyzed on sodium dodecyl sulfate (SDS)-polyacrylamide gels
containing gelatin (0.8 mg/ml). Prior to zymography, volumes of samples were
normalized on the basis of MTT activity or total protein content. Enzyme activity
was visualized as substrate degradation by negative staining with Coomassie
brilliant blue R250. Commercially available MMP-9 and MMP-2 were utilized as
positive controls. The gelatinase activity was quantified as densitometric units
(DU) by using the GelExpert software supplied with the Nucleovision gel imag-
ing system (Nucleo Tech Corp., Hayward, Calif.).
Immunohistochemical assays. Immunohistochemistry was performed on
5-mm-thick paraffin tissue sections as described previously (44). Human MDMs
or microglia were identified with anti-CD68 KP-1 (1:100; Dako) monoclonal
antibodies. Astrocytes were localized by glial fibrillary acidic protein (GFAP)
immunoreactivity (1:200; Dako). Antibodies to HLA-DR, CR3/43 (Boehringer
Mannheim), and HIV-1 p24 (Dako) were used at 1:25, 1:40, and 1:10 dilutions,
respectively. Antibodies to MMP-2 and MMP-9 (Labvision Corp., Fremont,
Calif.) were used at 1:50 and 1:10 dilutions, respectively. The avidin-biotin
immunoperoxidase staining was performed with the Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, Calif.) with 3, 39-diaminobenzidine (DAB) as
the chromogen. The sections were counterstained with Mayer’s hematoxylin.
RESULTS
MMP-1, -2, -3, and -9 regulation in MDMs and microglia.
We first studied MMP production by MPs following cell dif-
ferentiation, viral infection, and immune activation. Cross-val-
idating measurements of MMPs included RT-PCR, ELISA,
and zymography tests. Freshly elutriated monocytes and hu-
man microglial cells were used to determine how MP hetero-
geneity affects MMP expression. Monocytes were cultured for
1 day and then stimulated with CD40L (2 mg/ml). MMP levels
were measured by ELISA in culture fluids at 72 h after CD40L
addition. The levels of MMP-9 (Fig. 1A), MMP-2 (Fig. 1B),
MMP-3 (Fig. 1C), and MMP-1 (Fig. 1D) in both monocytes
and microglia are shown. CD40L-stimulated microglia gener-
ated significantly larger amounts of all MMPs than similarly
treated MDMs (Fig. 1; P , 0.01). MMP-3 was detected only in
culture supernatant of microglia (Fig. 1C). Microglia demon-
strated a significant upregulation in MMP-2 and -1 following
CD40L stimulation (Fig. 1B and D). Production of MMP-9
and MMP-1 by CD40L-stimulated microglia increased 10-fold
and 2-fold, respectively. Thus, activated microglia are capable
of secreting higher levels of MMPs than replicate MDMs. This
finding infers that microglial cells, when subjected to the ap-
propriate signals, could contribute to degradation of the neu-
ropil ECM during HAD.
MP differentiation affects MMP production. Increased infil-
tration of immune-activated monocytes, from blood to brain,
characterizes HAD. Importantly, monocyte transendothelial
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migration into brain occurs during macrophage differentiation.
To address whether differential MMP production between
monocytes, MDMs, and microglia reflects cellular differentia-
tion, we examined MMP production during cell differentiation.
MDMs were cultured for 10 days. At days 1, 3, 7, and 10,
MDMs were subjected to complete replacement of medium,
and MMP gene expression was analyzed by RT-PCR after an
additional 72 h, actin served as the internal standard for the
RT-PCR assays. Figure 2A demonstrates that expression of
both MMP-2 and MMP-9 increased during MDM differentia-
tion. MMP-9 mRNA increased 4.5-, 7.5-, and 22.5-fold at days
3, 7, and 10, respectively, after cell culture. The levels of
MMP-2 transcripts were 1.2-, 2.6-, and 9.2-fold higher at days
3, 7, and 10, respectively. The data demonstrate that cell dif-
ferentiation influences MMP production in MDM.
Brain MPs become immune-activated during HAD and in-
fluence disease progression. This can occur through a variety
of mechanisms, although proinflammatory cytokines, b-che-
mokines, and/or CD40L are likely candidates. To determine
the influence of immune activation on MMP production by
MPs, total MMP content of macrophage culture supernatants
was measured in the presence and absence of CD40L. Figure
2B and C show the levels of MDM MMP-9 (Fig. 2B) and
MMP-2 (Fig. 2C) produced after 1 and 7 days of cell culture
with or without 2 mg of CD40L stimulation per ml. The levels
of MMP-9 produced by MDMs at day 1 in control and CD40L-
activated cells were negligible, as determined by ELISA.
MMP-2 levels in MDMs were unchanged with or without
CD40L at 1 day (Fig. 2C). After 7 days of culture, unstimulated
MDMs generated 886 and 1,212 ng of MMP-9 per ml before
and after CD40L activation. The differences in MMP produc-
tion between days 1 and 7 were statistically significant (P ,
0.001). For MMP-2, the levels were 44 ng/ml for control
MDMs and 43 ng/ml with CD40L activation. These data im-
plied that the MMP-2 produced by MDMs had reached a
saturation point 7 days after cell cultivation. However, for
MMP-1, only immune-activated cells showed low, but detect-
able, amounts of enzyme (data not shown). These data support
the idea that cell differentiation is a principal driving force for
MMP production in MDMs.
To compare subtle differences in the levels of MMPs and to
ascertain the relative production of active MMP-9 and -2 from
MPs, gelatin zymography was used. In our experimental sys-
tems, zymography proved more sensitive than ELISA, with a
limit of detection of 3 pg. The zymograms obtained were an-
alyzed with densitometric scanning with band intensity ex-
pressed as DU. For the purpose of comparison, all sample
volumes were normalized by total protein content. To confirm
FIG. 1. MMP production in monocytes and human fetal microglia.
Monocytes and microglia were isolated and then cultivated in medium
with or without CD40L (2 mg/ml). Culture supernatants were collected
at 72 h after CD40L stimulation, and MMP levels were determined by
ELISA. Values represent the mean of triplicate determinations 6
standard error. MMP-9 (A), MMP-2 (B), MMP-3 (C), and MMP-1
(D) levels were compared. Statistical tests were performed with
GraphPad Prism 2.0, using one-way ANOVA with Newman-Keuls
posttest. These demonstrated that microglia generated significantly
higher levels of all MMPs when compared to monocytes (p, P , 0.01).
The effect of CD40L stimulation of microglial cells was also statistically
significant for MMP-2 and -1 (#; P , 0.001).
FIG. 2. Effect of MDM differentiation on MMP-9 and MMP-2
expression. (A) MDMs were cultured as adherent monolayers. Com-
plete exchange with serum-free medium was performed on days 1, 3, 7,
and 10. Total cellular RNA was analyzed for levels of MMP-9 and -2
by RT-PCR. Each time point was assayed in duplicate. Actin was
utilized as an internal standard. A time-dependent increase in the
levels of MMP RNA is shown. To assess the effect of immune activa-
tion in conjunction with differentiation, MDMs were stimulated with
CD40L (2 mg/ml) on culture days 1 and 7. Culture supernatant samples
were collected at 72 h after stimulation for MMP-9 (B) and MMP-2
(C) and tested by ELISA according to the manufacturer’s instructions.
At day 7 significantly larger amounts of both MMP-9 and -2 were
generated compared to those from day 1 (p, P , 0.001). MMP-9
production by MDMs was upregulated by CD40L at 7 days of cell
cultivation (#, P , 0.001). MMP-2 did not show significant differences
following cell activation (@, P . 0.05). Values represent the mean of
triplicate determination 6 standard error. Statistical analysis was per-
formed with GraphPad Prism 2.0, using one-way ANOVA with New-
man-Keuls posttest.
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the data set, each zymogram was performed with incremental
sample volumes on at least three separate gels. In addition,
representative samples were analyzed in triplicate and treated
as independent samples. A total of six individual MDM donors
and three microglia donors were studied. Figure 3 summarizes
the data obtained for the effects of cell differentiation (as
obtained in tissue culture) over time on pro- and active MMP-9
and -2.
The levels of MMP-9 and -2 produced by MDMs within 72 h
of culture were low and increased incrementally with time.
This led to a more than twofold increase in the pro-MMP-9
levels (Fig. 3A and B). Microglia, in contrast, generated high
levels of MMPs de novo, which did not change significantly
over time in culture. This pattern of MMP production was
reflected in pro-MMP-9 and pro-MMP-2 and their active
forms (Fig. 3B, C, D, and E). This also suggests that differen-
tiation of cells in vitro not only led to the increase in the total
MMP production, but also led to an increase in levels of their
FIG. 3. MDMs secrete pro- and active MMP-9 and MMP-2. MDMs and microglia were cultured as adherent monolayers. Complete medium
exchange was performed at the time points indicated, and culture supernatants were tested by zymography after 72 h. A representative zymogram
obtained from days 1, 3, 7, and 10 is shown in panel A. Levels of pro-MMP-9 (92 kDa) (B) and pro-MMP-2 (72 kDa) (C) and their active forms
(active MMP-9 [D] and active MMP-2 [E], respectively) were quantified densitometrically and compared. Data are representative of a total of six
MDM donors and two microglia donors performed three or more times on multiple gels.
VOL. 75, 2001 MATRIX METALLOPROTEINASES AND MONONUCLEAR PHAGOCYTES 6575
 
active forms. The production of large amounts of pro-MMPs
would simply represent a pool of enzyme molecules available
for activation upon receipt of the appropriate stimuli, while the
generation of the active forms would represent enzyme activity
directly available to the cells that are attempting to traverse the
BBB.
Regulation of TIMP-1 during monocyte differentiation. Our
initial observations led us to investigate the levels of MP tissue
inhibitor of metalloproteinase-1 (TIMP-1), because TIMPs
regulate MMP activity in the extracellular milieu. TIMP-1 and
-2 are the two types of inhibitors produced by MP. TIMP-2
generally is expressed constitutively, whereas TIMP-1 is induc-
ible. We determined the levels of TIMP-1 during differentia-
tion in the presence and absence of CD40L (Fig. 4). Levels of
TIMP-1 increased with differentiation, together with MMP-9.
TIMP-1 production increased 3.4-fold from day 1 to day 7 (P ,
0.001). Also, CD40L led to a significant increase in TIMP-1
levels in MDMs stimulated at day 7 in culture (P , 0.001).
Thus, during brain tissue infiltration in HAD, the increase in
MMPs is perhaps balanced with the higher levels of TIMP-1. It
is noteworthy, however, that the TIMP-1 ELISA measured
total TIMP-1, including both free TIMP-1 and that complexed
with MMP-1, -2, -3, and -9.
MMP production in MDM following HIV-1 infection. Next,
we examined the effects of HIV-1 infection on the production
of MMP-9 and -2 by macrophages. MDMs were cultivated for
a period of 7 days to permit cell differentiation. Cells were then
infected with HIV-1ADA. MMP-9 expression was determined
by RT-PCR and normalized to the levels of actin (Fig. 5A).
Several donors were analyzed, and representative data are
shown. The observed down-modulation of MMPs by HIV-
1ADA was statistically significant (P , 0.05). Importantly, the
data demonstrating a down-modulation of MMP-9 stand in
contrast to previously published observations by Dhawan et al.
(11) in which HIV-1ADA-infected MDMs demonstrated a two-
fold increase in pro-MMP-9. We confirmed our observations in
subsequent experiments by gelatin zymography, which is cur-
rently a sensitive tool for detection of subtle changes in MMP
levels. Figure 5B shows three experiments performed with
independent MDM donors that demonstrated similar trends of
down-regulation of MMP-9 following viral infection. In the
study performed by Dhawan et al. (11), pro-MMP-9 levels
were measured 12 h after complete exchange of medium. In
our systems, the MMP-9 levels were measured 48 h after me-
dium exchange. Thus, the differences in the observations could
reflect the differences in the experimental systems used. The
proteins, once secreted, would lead to a cumulative effect as a
function of time, whereas the transcripts would be upregulated
transiently. In our experimental system, both the mRNA and
the protein levels of MMP-9 at 48 h were significantly down-
regulated. We thus measured MMP-9 levels in culture super-
natant samples obtained from MDMs infected with multiple
other central nervous system (CNS) donors (Fig. 5C). We
utilized HIV-1YU-2, HIV-1JR-FL, and HIV-1DJV as brain iso-
FIG. 4. Secretory levels of TIMP-1 produced by MDMs. Freshly
elutriated monocytes were cultured as adherent monolayers. At days 1,
3, and 7, cells were stimulated with 2 mg of CD40L per ml for 72 h, and
TIMP-1 levels in the culture supernatant were analyzed by ELISA.
Each sample was analyzed in triplicate. Levels of TIMP-1 were up-
regulated 3.4-fold from day 1 to day 7 (p, P , 0.001). In addition,
CD40L stimulation led to a statistically significant increase in TIMP-1
levels in cells stimulated on day 7 of culture (pp, P , 0.001). Repre-
sentative data obtained from a total of three donors are shown. Values
represent the mean of triplicate determinations 6 standard error.
Statistical analysis was performed with GraphPad Prism 2.0, using
one-way ANOVA with Newman-Keuls posttest.
FIG. 5. Regulation of MMP expression in HIV-1-infected MDM.
(A) Adherent monolayers of MDMs were maintained for 7 days prior
to infection with HIV-1ADA. Triplicate wells of infected or uninfected
control cells had complete medium exchange at day 5 postinfection.
Cells were maintained for an additional 48 h. MDMs were harvested in
TRIzol, and total RNA was extracted. MMP mRNA was detected by
RT-PCR. Representative data for MMP-9 mRNA are shown. Actin
was utilized as the internal standard for semiquantitative comparison.
HIV-1ADA significantly down-regulated the levels of MMP-9 mRNA
(A, p, P , 0.05). (B) MDMs were infected as described for panel A.
MMP levels in culture supernatant samples from HIV-1-infected and
uninfected cells were analyzed by zymography. Culture supernatant
volumes were normalized on the basis of endpoint MTT activity. Three
independent donors are represented. (C) Secretory profiles of MMP-9
in culture supernatant samples derived from uninfected and HIV-1-
infected cells with or without CD40L stimulation were analyzed by
ELISA. Three CNS HIV-1 isolates (HIV-1YU-2, HIV-1DJV, and HIV-
1JR-FL) and two cerebrospinal fluid HIV-1 isolates (HIV-1SF162 and
HIV-1MSCSF) were utilized. All isolates except for HIV-1YU-2 led to a
significant down-regulation in MMP-9 levels in infected cells (p, P ,
0.001). CD40L stimulation led to a statistically significant upregulation
in MMP-9 levels in uninfected and HIV-1-infected cells, with the
exception of HIV-1YU-2 (P , 0.01). Statistical analysis was performed
with GraphPad Prism 2.0, using one-way ANOVA with Newman-
Keuls posttest.
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lates and HIV-1SF162 and HIV-1MSCSF as those obtained from
cerebrospinal fluid samples. All demonstrated significant
down-regulation compared to uninfected cells (P , 0.001).
This down-regulation by infection with HIV-1DJV, HIV-1JR-FL,
HIV-1MSCSF, and HIV-1SF162 was significantly reversed with
CD40L activation (P , 0.01).
MMPs expressed in HIV-1-infected human brain tissue. In
order to correlate our laboratory observations with those in an
infected person, we investigated the levels of MMP-9 and -2 in
brain tissue from human autopsy specimens. This was per-
formed by semiquantitative comparisons of MMP transcripts
by RT-PCR analysis and immunohistochemical staining for
MMP antigens. Brains of patients who died of HIVE, HIV-1
disease without neurological complications and controls (pa-
tients with systemic diseases not related to brain dysfunction)
were examined. Total RNA was extracted from brain tissue
derived from three control, five HIV-1-seropositive, and seven
HIVE subjects. In most cases, RNA extractions were per-
formed on two distinct areas of the brain—the frontal cortex
and the basal ganglia. For semiquantitative comparisons, actin
was utilized as the internal control. The data are summarized
in Fig. 6. Representative RT-PCR data from three indepen-
dent donors from each group are shown in Fig. 6A, and a
summary of the comparisons obtained for MMP-9 and -2 with
all patients and control subjects is shown in Fig. 6B and C,
respectively. HIVE led to statistically significant increases in
MMP-9 transcripts compared to those in controls (P , 0.05).
The levels of MMP-2 transcripts were higher than those in
controls, although they were not statistically significant. A cor-
relation determined by RT-PCR showed that the levels of both
MMP-9 and -2 in HIVE patients correlated with CD14 levels
normalized to actin products (correlation coefficient, r2 5
0.9593 for MMP-9 and r2 5 0.9412 for MMP-2). Comparisons
between control and HIV-1-seropositive donors yielded corre-
lation coefficients below 0.5. These data suggest that the higher
levels of MMP transcripts in HIVE brain tissue were a result of
the increased numbers of immune-competent MP in these
patients. In order to colocalize MMP antigens with specific cell
types, we next performed immunohistochemical analysis with
antibodies to MMP-9 and -2 on areas adjacent to the brain
regions utilized for RNA extraction. Serial sections were uti-
lized to identify specific cell types expressing MMPs in brain
parenchyma.
For the immunohistochemical analyses, we examined a total
of 15 brain autopsy samples, including 6 from patients with
severe HIVE, 3 from patients with mild HIVE, 3 from HIV-1
seropositive patients without HIVE, and 3 from controls with
neither HIV-1 infection nor encephalitis (Fig. 7 and 8). Four of
the HIVE, three of the HIV-1-seropositive, and one of the
control samples were kindly provided via the Manhattan Brain
Bank. Results of the MMP-2 cell localization and extent of
antigen expression are summarized in Fig. 7. Panels A to F and
H show results from HIVE brain tissue, and panel G shows
results from control brain tissue. Neuropathological analyses
of HIVE brain tissue showed a direct relationship between
microglial accumulation and activation (detected as HLA-DR
FIG. 6. Levels of MMP transcripts in human brain tissue. Total cellular RNA was extracted from frontal cortex and basal ganglia tissue
obtained from three controls, five HIV-seropositive patients, and four HIVE patients. MMP-9 and -2 transcripts were detected by RT-PCR as
described in Materials and Methods. Actin was used as an internal control for semiquantitative comparisons. Each sample was analyzed in
duplicate determinations. Panel A illustrates three representative donors each from control, HIV-positive, and HIVE groups. Panels B and C
summarize the data obtained with all patients investigated for MMP-9 and MMP-2 levels, respectively. Values represent the mean of duplicate
determinations 6 standard error. Statistical analysis was performed with GraphPad Prism 2.0, using one-way ANOVA with Newman-Keuls
posttest. Levels of MMP-9 between HIVE and control brain tissue were significantly different (p, P , 0.05).
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FIG. 7. Cellular localization of MMP-2 in human brain tissue. Fifteen brain autopsy samples were analyzed, including those from 3 control
subjects (without CNS disease), 6 patients with severe HIVE, 3 patients with mild HIVE, and 3 HIV-1-seropositive patients without nervous system
disease. In the patients with severe HIVE, prominent astrogliosis as identified by GFAP immunoreactivity was observed (A). HIV-1-infected
multinucleated giant cells (B) expressed MMP-2 and were prominent in areas with significant monocyte infiltration. Serial sections stained with
MMP-2 (C), CD68 (D), HLA-DR (E), and HIV-1 p24 (F) demonstrated activated, HIV-1-infected cells in microglial nodules positive for MMP-2.
Control mouse IgG served as the negative control (H). Few MMP-2 antigen-positive endothelial cells were observed in the control samples (G).
Sections are stained with GFAP (A), MMP-2 (B, C, and G), HLA-DR (E), HIV-1 p24 (F), and control IgG (H). Immunoreactivity was detected
with a Vectastain Elite kit with DAB as a substrate. Tissue sections were counterstained with Mayer’s hematoxylin. Original magnification, panels
A and C to H, 3200; panel B, 3400.
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expression and transformation of ramified microglia into
amoeboid form), formation of microglial nodules, the intensity
of macrophage infiltration, and MMP expression within infil-
trating inflammatory cells, perivascular macrophages, and mi-
croglial nodules. These changes were accompanied by a pro-
nounced astrogliosis. The amount of plump reactive astrocytes
was significantly increased compared to that in controls (Fig.
7A). In addition, a significant accumulation of microglial cells
and clear signs of microglia activation (HLA-DR staining)
were present in areas with reactive astrogliosis (Fig. 7E). In
parallel, perivascular macrophages (cells with abundant cyto-
plasm) and monocytes that had migrated into the brain (small-
er round cells) expressed high levels of HLA-DR. They were
localized immediately at the abluminal surface of brain micro-
vascular endothelial cells, a major component of the BBB.
Perivascular cells and some microglia were HIV-1 p24 immu-
noreactive (Fig. 7F). Endothelial cells and smooth muscle cells
expressing MMP-2 antigens were frequently observed (Fig. 7B
and G). Occasional single and multinucleated giant MPs were
also MMP-2 immunoreactive in close proximity to microvessels
(Fig. 7B). Microglial nodules present in the brain parenchyma
were identified by immunostaining with CD68 (a mononuclear
phagocyte marker) (Fig. 7D) and for HLA-DR (Fig. 7E). Cells
in microglial nodules were positive for MMP-2 (Fig. 7C) and
HIV-1 p24 (Fig. 7F). HIVE serial sections immunostained with
mouse immunoglobulin G (IgG) for nonspecific control did
not demonstrate any immunoreactivity (Fig. 7H). Specificity of
MMP-2 and MMP-9 antibodies was confirmed with human
placental sections as positive controls (data not shown). Brain
tissue derived from control HIV-1-seropositive patients and
HIV-1-negative control subjects showed nonspecific changes
with minimal expression of HLA-DR in less than 10% of
microglia located in white matter. Astrogliosis was absent, and
GFAP-positive astrocytes showed long slender processes.
Moderate expression of MMP-2 was found on endothelial cells
and on a few smooth muscle cells in controls without neuro-
logical disease (Fig. 7G). Neither parenchymal microglia nor
occasional perivascular macrophages showed expression of
MMP-2.
Figure 8 summarizes the data obtained for MMP-9. MMP-9
expression (Fig. 8A) in HLA-DR-positive (Fig. 8C) microglial
cells was observed in patients with mild cases of HIVE and
HIV-1-seropositive patients. These cells were readily positive
for CD68 (a marker for MP) (Fig. 8B). It is important to note
that MMP-9 immunoreactivity colocalized well with a marker
of immune activation (HLA-DR [Fig. 8C]). However, localiza-
tion by HIV-1 p24 on serial sections showed minimal viral
infection (Fig. 8D). Interestingly, all samples examined dem-
onstrated additional MMP-9 localization in axon-like linear
structures (Fig. 8A and E). A nonneurological control sample
showed MMP-9 staining mainly in linear structures (Fig. 8E).
The identity of these linear tracks of MMP-9 immunoreactivity
is yet to be confirmed. These studies confirm the importance of
MMPs in conjunction with immune activation of MPs in the
brain and its implication for the progression of HAD. In toto,
analysis of human brain tissue showed that HIVE is associated
mainly with MP activation, traffic of activated macrophages,
and astrogliosis and that these activities were correlated with
expression of MMPs.
DISCUSSION
Our results demonstrate that heterogeneity exists among
MPs with regard to MMP regulation. Under steady-state con-
ditions, MMPs maintain the brain’s ECM through remodeling
of the neuropil. MMPs play an important role in BBB com-
promise. Migration of T lymphocytes and monocytes across
basement membranes and their infiltration into the neuropil
are ensured by the production of MMPs (32). Indeed, several
studies have convincingly demonstrated the role of MMPs in
affecting BBB permeability and endothelial cell function (50–
52). Bacterial collagenases disrupt ECM and destroy the in-
tegrity of the BBB (51). Alterations in monocyte-endothelial
cell interactions are also dependent on MMPs (11). Notably,
the interactions between monocytes with both microvascular
endothelial cells and resident astrocytes form a tripartite
MMP-producing complex that can affect cell recruitment into
brain. During CNS disease, MMP production is enhanced,
leading to the degradation of the ECM and loss of its homeo-
static remodeling function. Also, monocyte infiltration in the
brain increases during HAD progression, and these newly re-
cruited macrophages would be responsible for enhancement of
MMPs and consequent disease progression. Indeed, our data
show that perivascular leukocytes associated with HIVE ex-
press both MMP-2 and MMP-9. Our works and those of others
support a relationship between macrophage numbers and neu-
ropil alterations. For example, in Alzheimer’s disease, matrix-
degrading enzymes have been implicated in the development
of senile dementia (3). Moreover, in studies of 27 individuals
with advanced HIV-1 infection, it was shown that 9 of 9 who
had HIVE were completely devoid of labeled ECM. Eight of
18 subjects without HIVE had substantial losses of ECM, and
only 2 manifested a normal ECM complement. The data
showed that a severe compromise in ECM integrity occurs in
the neuropil during HIVE (1).
Under homeostatic conditions, microglia are present as ter-
minally differentiated ramified cells that can undergo dediffer-
entiation during injury. As proposed for HAD, microglia can
be recruited to sites of neural injury and undergo proliferative
responses (12). It is of interest that brain MPs (microglia, as
compared to MDMs) differ in their capacity to secrete MMPs.
This might enable the cells to perform dual functions in dis-
ease. First, differentiated brain macrophages could enhance
continued penetration of monocytes through the BBB. This
hypothesis is supported by the presence of perivascular mac-
rophages in areas of diseased brain with microgliosis and signs
of MP activation. Second, the ability of macrophages and/or
microglia to directly degrade the brain ECM may affect neu-
rodegeneration. Given the fact that monocytes differentiate
during brain migration, MMP production by infiltrating cells
would continue. Once inside the brain, MP activation would
allow the secretion of chemokines and other inflammatory
molecules, serving to amplify secretory neurotoxic activities
resulting in further brain monocyte migration. Our data were
obtained by utilizing fetal microglial cells and comparing them
to adult MDMs, and the possibility that the intrinsic MMP
profiles in these cells may be different remains open. However,
we have previously demonstrated comparisons consistent with
the data presented in this work (20, 22, 44)
Interestingly, we also found a concomitant increase in
VOL. 75, 2001 MATRIX METALLOPROTEINASES AND MONONUCLEAR PHAGOCYTES 6579
TIMP-1 production. TIMP-1 preferentially binds to pro-
MMP-9; however, it can inhibit the activity of all active MMPs.
In addition, TIMP-1 is the inducible tissue inhibitor of MMPs,
as compared to TIMP-2, which is believed to have a constitu-
tive expression pattern. These studies clearly demonstrate that
a balance between the levels of MMPs and their tissue inhib-
itors in the BBB microenvironment determines ECM break-
down mediated by infiltrating monocytes. Ultimately, MP ac-
FIG. 8. MMP-9 localization in human brain tissue. Expression of MMP-9 was evaluated for all subjects as described for MMP-2. MMP-9
expression was detected on microglial nodules in brain tissue of HIV-1-seropositive patients devoid of neurological complications (A). Serial
sections stained with CD68 (B [MP marker]) showed that some of these cells demonstrating MMP-9 reactivity were activated MPs. Importantly,
the majority of MMP-9-positive cells expressed HLA-DR, a marker for activation (C), yet were minimally infected, as demonstrated by a lack of
HIV-1 p24 detection (D). Interestingly, in a nonneurological control subject, MMP-9 immunoreactivity was observed mainly on linear axon-like
processes (E) and was absent on MPs (F). Staining for MMP-9 (A and E), CD68 (B and F), HLA-DR (C), and HIV-1 p24 (D) is shown. Original
magnifications: A to E, 3200; F, 3100.
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tivation, differentiation, and/or viral infection would result in
the amplification of brain inflammation and progressive neural
impairment.
The role of MP immune activation in HIV neuropathogen-
esis is underscored by our observation that CD40L stimulation
can reverse the MMP-9 down-regulation induced by viral in-
fection. Our data show that CD40L activation of differentiating
MPs leads to significant increases in MMP production. Al-
though the biological source of CD40L is unclear, it remains an
important physiological immune activator relevant to HAD.
Human vascular endothelial cells express CD40 antigen and
produce functional CD40L (37). The notion that CD40L pro-
duced by endothelial cells leads to an upregulation in MP
MMPs is attractive, although, perhaps oversimplified. Indeed,
the interactions between transmigrating monocytes and endo-
thelial cells involve astrocytes, an integral part of the BBB.
Since astrocytes also express CD40 receptor, they too are can-
didates for CD40L-mediated activation. In addition, astrocytes
and endothelial cells, as well as MPs, are capable of generating
MMPs. There is likely a complex intercellular dialogue that is
mediated, only in part, by MMP production by MPs. Indeed,
the restoration of high levels of MMP-9 in MPs after CD40L
stimulation reflects the critical importance of immune activa-
tion in HIVE pathogenesis and the relevance of our laboratory
findings to what is observed in an infected human host.
Our results demonstrate a consistent down-regulation in
MMP-9, as determined by multiple assays, including RT-PCR,
ELISA, and gelatin zymography. Importantly, our assays ex-
amine MMP-9 production on a single-cell basis, and the results
were confirmed in multiple donors. These results appear to be
at odds with previously published reports (9, 11, 36, 54, 59).
These studies assayed biological material such as patient
plasma or cerebrospinal fluid to show net increases in MMP-9
production, but could not detect whether higher production by
each cell was occurring. Indeed, the studies performed by Li-
uzzi et al. (36) and Sporer et al. (54) demonstrated increased
pleiocytosis in the cerebrospinal fluid concomitant with
MMP-9 levels. Thus, we propose that the MMP-9 levels during
disease reflect increases in numbers of immune-competent
MPs in the brain due to increased trafficking of activated mac-
rophages and resident microglial activation. It has been previ-
ously shown by Glass et al. (25) that the best histopathologic
correlate of HAD is the number of inflammatory macrophages
in the CNS. The phenomenon of down-regulation of MMP-9
production by HIV-1 infection is nonetheless intriguing.
MMP-9 production in MPs involves the signal transduction
pathways mediated by the mitogen-associated protein (MAP)
kinase. Interestingly, the infection of host cells by HIV-1 is also
linked to MAP kinase pathways (2, 62, 63). In addition, works
published on the phosphorylation of HIV-1 matrix show that
HIV-1 virions package the cellular MAP kinase enzyme in the
viral particles, which is responsible for the phosphorylation of
matrix and the nuclear import of the viral preintegration com-
plex (29, 56). We propose that due to the packaging of the
cellular MAP kinase molecules in budding virions, the MMP-9
production is down-regulated due to a compromise in available
kinase activity in the cellular milieu. This is further supported
by the fact that activation of infected cells with CD40L, which
is known to upregulate the MAP kinase pathway, reverses the
effect of HIV-1-mediated down-regulation of MMP-9. This
hypothesis is currently under investigation.
We also demonstrated that MMP-2 expression in HIVE
brain tissue was observed on microglial nodules in the subcor-
tical white matter, perivascular and multinucleated macro-
phages, and microvascular endothelial cells. Interestingly,
MMP-9 expression was most commonly observed on longitu-
dinal tracks and was rarely observed on microglial nodules
associated with severe encephalitis. In addition, MMP-9-posi-
tive microglial nodules were occasionally observed in HIV-1-
infected individuals devoid of neurological disease. However,
MMP-2 was not detected. MMP-9 was detected in perivascular
macrophages in brain tissue with subtle signs of HIVE. Our
observations also suggest that even a minimal increase in cell
numbers and, more importantly, the state of MP immune ac-
tivation might be sufficient to induce neurological dysfunction.
In support of this idea is the observation that widespread
microglial activation and accompanying reactive astrogliosis
are found in the areas with the most pronounced dendritic
alterations (39). Synaptic loss, also linked to MP activation, is
now the best correlate of clinical cognitive deterioration in
HAD (40). Three-dimensional stereological measures show
a significant correlation between reduced synaptic density
and poor neuropsychological performance. We also observed
MMP-9 immunoreactivity on axon-like linear tracks in white
matter. These data underscore the significance of traffic of
activated macrophages into the brain and immune activation of
microglia in HAD pathogenesis.
Our works, along with those of others, imply that multiple
mechanisms are operative for MMP production and its reg-
ulation during neurodegenerative disease. Both microglia
and infiltrating monocytes can produce MMPs in response to a
variety of immune stimuli and/or viral infection. Either factor
is readily available in the BBB or CNS microenvironment.
Given this information, we speculate that in HAD, MMP in-
hibitors might prevent the influx of inflammatory cells through
the BBB and help prevent damage to the neuropil’s ECM.
Indeed, such inhibitors have been effectively used in experi-
mental autoimmune encephalitis, the animal model for multi-
ple sclerosis (8, 35) and the SCID mouse model for HIVE (45).
Thus, treatment with MMP inhibitors may aid in repression of
the immune effector responses of macrophages in addition to
their direct effects on MMP activity. Altogether these obser-
vations strongly suggest a role for MMPs in disease progres-
sion. Thus, the potential to halt their production may influence
the course and severity of cognitive dysfunction in HIV-1-
infected individuals.
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